Journal
CELL DEATH & DISEASE
Volume 12, Issue 2, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41419-021-03497-y
Keywords
-
Categories
Funding
- Cancer Research UK [A29800]
- CRUK Beatson Institute [A17196]
- HDF fellowship of the Welcome Trust [WT101242AIA]
- CRUK
- University of Manchester
- MRC [MC_UP_1203/3, MR/P01058X/1] Funding Source: UKRI
Ask authors/readers for more resources
Mutant p53 protein can facilitate the cell membrane recycling of P-gp through RCP, leading to chemoresistance. Cells without RCP or mutant p53 show increased sensitivity to cisplatin and etoposide.
TP53 is the most frequently mutated gene in cancers. Mutations lead to loss of p53 expression or expression of a mutant protein. Mutant p53 proteins commonly lose wild-type function, but can also acquire novel functions in promoting metastasis and chemoresistance. Previously, we uncovered a role for Rab-coupling protein (RCP) in mutant p53-dependent invasion. RCP promotes endosomal recycling and signalling of integrins and receptor tyrosine kinases. In a screen to identify novel RCP-interacting proteins, we discovered P-glycoprotein (P-gp). Thus, we hypothesised that mutant p53 could promote chemoresistance through RCP-dependent recycling of P-gp. The interaction between RCP and P-gp was verified endogenously and loss of RCP or mutant p53 rendered cells more sensitive to cisplatin and etoposide. In mutant p53 cells we detected an RCP-dependent delivery of P-gp to the plasma membrane upon drug treatment and decreased retention of P-gp substrates. A co-localisation of P-gp and RCP was seen in mutant p53 cells, but not in p53-null cells upon chemotherapeutic exposure. In conclusion, mutant p53 expression enhanced co-localisation of P-gp and RCP to allow for rapid delivery of P-gp to the plasma membrane and increased resistance to chemotherapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available